TY  - JOUR
AU  - Vekić, Jelena
AU  - Zeljković, Aleksandra
AU  - Stefanović, Aleksandra
AU  - Bogavac-Stanojević, Nataša
AU  - Ilias, Ioannis
AU  - Silva-Nunes, José
AU  - Pantea Stoian, Anca
AU  - Janez, Andrej
AU  - Rizzo, Manfredi
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4100
AB  - Compelling evidence supports the causative link between increased levels of low-density lipoprotein cholesterol (LDL-C) and atherosclerotic cardiovascular disease (CVD) development. For that reason, the principal aim of primary and secondary cardiovascular prevention is to reach and sustain recommended LDL-C goals. Although there is a considerable body of evidence that shows that lowering LDL-C levels is directly associated with CVD risk reduction, recent data shows that the majority of patients across Europe cannot achieve their LDL-C targets. In attempting to address this matter, a new overarching concept of a lipid-lowering approach, comprising of even more intensive, much earlier and longer intervention to reduce LDL-C level, was recently proposed for high-risk patients. Another important concern is the residual risk for recurrent cardiovascular events despite optimal LDL-C reduction, suggesting that novel lipid biomarkers should also be considered as potential therapeutic targets. Among them, small dense LDL particles (sdLDL) seem to have the most significant potential for therapeutic modulation. This paper discusses the potential of traditional and emerging lipid-lowering approaches for cardiovascular prevention by targeting sdLDL particles.
PB  - MDPI
T2  - Pharmaceutics
T1  - Novel Pharmaceutical and Nutraceutical-Based Approaches for Cardiovascular Diseases Prevention Targeting Atherogenic Small Dense LDL
VL  - 14
IS  - 4
DO  - 10.3390/pharmaceutics14040825
ER  - 

@article{
author = "Vekić, Jelena and Zeljković, Aleksandra and Stefanović, Aleksandra and Bogavac-Stanojević, Nataša and Ilias, Ioannis and Silva-Nunes, José and Pantea Stoian, Anca and Janez, Andrej and Rizzo, Manfredi",
year = "2022",
abstract = "Compelling evidence supports the causative link between increased levels of low-density lipoprotein cholesterol (LDL-C) and atherosclerotic cardiovascular disease (CVD) development. For that reason, the principal aim of primary and secondary cardiovascular prevention is to reach and sustain recommended LDL-C goals. Although there is a considerable body of evidence that shows that lowering LDL-C levels is directly associated with CVD risk reduction, recent data shows that the majority of patients across Europe cannot achieve their LDL-C targets. In attempting to address this matter, a new overarching concept of a lipid-lowering approach, comprising of even more intensive, much earlier and longer intervention to reduce LDL-C level, was recently proposed for high-risk patients. Another important concern is the residual risk for recurrent cardiovascular events despite optimal LDL-C reduction, suggesting that novel lipid biomarkers should also be considered as potential therapeutic targets. Among them, small dense LDL particles (sdLDL) seem to have the most significant potential for therapeutic modulation. This paper discusses the potential of traditional and emerging lipid-lowering approaches for cardiovascular prevention by targeting sdLDL particles.",
publisher = "MDPI",
journal = "Pharmaceutics",
title = "Novel Pharmaceutical and Nutraceutical-Based Approaches for Cardiovascular Diseases Prevention Targeting Atherogenic Small Dense LDL",
volume = "14",
number = "4",
doi = "10.3390/pharmaceutics14040825"
}

Vekić, J., Zeljković, A., Stefanović, A., Bogavac-Stanojević, N., Ilias, I., Silva-Nunes, J., Pantea Stoian, A., Janez, A.,& Rizzo, M.. (2022). Novel Pharmaceutical and Nutraceutical-Based Approaches for Cardiovascular Diseases Prevention Targeting Atherogenic Small Dense LDL. in Pharmaceutics
MDPI., 14(4).
https://doi.org/10.3390/pharmaceutics14040825

Vekić J, Zeljković A, Stefanović A, Bogavac-Stanojević N, Ilias I, Silva-Nunes J, Pantea Stoian A, Janez A, Rizzo M. Novel Pharmaceutical and Nutraceutical-Based Approaches for Cardiovascular Diseases Prevention Targeting Atherogenic Small Dense LDL. in Pharmaceutics. 2022;14(4).
doi:10.3390/pharmaceutics14040825 .

Vekić, Jelena, Zeljković, Aleksandra, Stefanović, Aleksandra, Bogavac-Stanojević, Nataša, Ilias, Ioannis, Silva-Nunes, José, Pantea Stoian, Anca, Janez, Andrej, Rizzo, Manfredi, "Novel Pharmaceutical and Nutraceutical-Based Approaches for Cardiovascular Diseases Prevention Targeting Atherogenic Small Dense LDL" in Pharmaceutics, 14, no. 4 (2022),
https://doi.org/10.3390/pharmaceutics14040825 . .